by Dr. Ed Weber | Jan 19, 2021 | PCa Commentary
Active surveillance (AS) is an increasingly recommended strategy for carefully selected men with a biopsy diagnosis of low grade, localized prostate cancer. It involves delaying primary intervention with careful follow-up monitoring with a goal of avoiding...
by Dr. Ed Weber | Oct 7, 2020 | PCa Commentary
In 2013 Radium-223 was FDA approved for treatment of prostate cancer patients with bone metastases on the basis of a large randomized trial, ASYMPCA, comparing the radioisotope to a placebo. In 708 heavily pretreated men, the overall median survival was extended by...
by Dr. Ed Weber | Oct 7, 2020 | PCa Commentary
Following radical prostatectomy [and radiation therapy] for organ confined disease, approximately one-third of men will develop a biochemical relapse with a detectable PSA level.” Quoted from “PSA Doubling Time and Absolute PSA Predict Metastases-free Survival in Men...
by Dr. Ed Weber | Feb 26, 2020 | PCa Commentary
Three new modalities for treatment of advanced prostate cancer are in development that will significantly impact management and extend overall survival: immunotherapy with checkpoint blockade; poly ADP-ribosepolymerase (PARP) inhibitors; and anti-PSMA radioligand...